Cullinan Oncology LLC (CGEM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $667.39M
Last updated: Nov 17, 2026 at 11:05 AM ET
Cullinan Oncology LLC (CGEM) Earnings: Report Dates and Results
Cullinan Oncology LLC (CGEM) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Cullinan Oncology LLC reported EPS of -$0.74, above the -$0.79 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CGEM has an expected report date of Mar 8, 2027.
Earnings History
Of the 24 quarters below that had an estimate, CGEM beat 15 and missed 9. The widest gap in the table came in the quarter ended Dec 31, 2020, when EPS landed 652.63% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.74 | -$0.79 | -$1.04 - -$0.71 | +6.33% | Beat | N/A | 9 | 2 up, 0 down | Nov 10, 2026 |
| Jun 30, 2026 | -$0.81 | -$0.71 | N/A | -14.08% | Miss | N/A | 9 | 2 up, 1 down | Aug 6, 2026 |
| Mar 31, 2026 | -$0.75 | -$0.84 | -$0.93 - -$0.75 | +10.71% | Beat | N/A | 8 | 1 up, 0 down | May 7, 2026 |
| Dec 31, 2025 | -$0.77 | -$0.87 | -$0.99 - -$0.49 | +11.89% | Beat | N/A | 9 | 2 up, 1 down | Mar 10, 2026 |
| Sep 30, 2025 | -$0.77 | -$0.89 | -$0.98 - -$0.81 | +13.48% | Beat | N/A | 8 | 1 up, 5 down | Nov 6, 2025 |
| Jun 30, 2025 | -$1.07 | -$0.83 | -$1.14 - -$0.71 | -28.92% | Miss | N/A | 7 | 2 up, 2 down | Aug 7, 2025 |
| Mar 31, 2025 | -$0.74 | -$0.81 | -$0.90 - -$0.75 | +8.64% | Beat | N/A | 7 | 1 up, 0 down | May 8, 2025 |
| Dec 31, 2024 | -$0.73 | -$0.74 | -$0.94 - -$0.60 | +1.66% | Beat | N/A | 8 | 1 up, 0 down | Feb 27, 2025 |
| Sep 30, 2024 | -$0.69 | -$0.77 | -$0.99 - -$0.69 | +10.39% | Beat | N/A | 10 | 0 up, 0 down | Nov 7, 2024 |
| Jun 30, 2024 | -$0.75 | -$0.73 | -$0.89 - -$0.62 | -2.74% | Miss | N/A | 9 | 0 up, 0 down | Aug 8, 2024 |
| Mar 31, 2024 | -$0.86 | -$0.99 | -$1.42 - -$0.72 | +13.13% | Beat | N/A | 9 | 1 up, 0 down | May 15, 2024 |
| Dec 31, 2023 | -$0.54 | -$0.98 | -$1.00 - -$0.91 | +44.90% | Beat | N/A | 7 | 0 up, 0 down | Mar 14, 2024 |
| Sep 30, 2023 | -$0.91 | -$0.94 | -$1.07 - -$0.82 | +3.19% | Beat | N/A | 6 | 0 up, 0 down | Nov 8, 2023 |
| Jun 30, 2023 | -$0.82 | -$1.00 | -$1.31 - -$0.85 | +18.00% | Beat | -121.8% | 5 | 0 up, 0 down | Aug 10, 2023 |
| Mar 31, 2023 | -$1.42 | -$0.98 | -$1.39 - -$0.59 | -44.90% | Miss | N/A | 4 | 0 up, 0 down | May 11, 2023 |
| Dec 31, 2022 | -$0.59 | -$0.71 | -$0.87 - -$0.48 | +16.90% | Beat | N/A | 4 | 0 up, 0 down | Mar 9, 2023 |
| Sep 30, 2022 | -$0.54 | -$0.97 | -$1.50 - -$0.63 | +44.33% | Beat | N/A | 3 | 0 up, 0 down | Nov 14, 2022 |
| Jun 30, 2022 | $3.77 | $5.42 | $5.40 - $5.44 | -30.44% | Miss | N/A | 3 | 0 up, 0 down | Aug 10, 2022 |
| Mar 31, 2022 | -$0.27 | -$0.55 | N/A | +50.91% | Beat | N/A | 3 | 0 up, 0 down | May 16, 2022 |
| Dec 31, 2021 | -$0.74 | -$0.47 | -$0.54 - -$0.44 | -57.45% | Miss | N/A | 3 | 0 up, 0 down | Mar 17, 2022 |
| Sep 30, 2021 | -$0.50 | -$0.43 | N/A | -16.28% | Miss | N/A | 2 | 2 up, 0 down | Nov 9, 2021 |
| Jun 30, 2021 | -$0.36 | -$0.42 | -$0.42 - -$0.41 | +14.29% | Beat | N/A | 2 | N/A | Aug 10, 2021 |
| Mar 31, 2021 | $0.00 | $0.03 | $0.03 - $0.10 | -105.67% | Miss | N/A | 2 | N/A | May 14, 2021 |
| Dec 31, 2020 | -$2.86 | -$0.38 | -$0.48 - -$0.29 | -652.63% | Miss | N/A | 2 | N/A | Jan 6, 2021 |
| Sep 30, 2020 | -$0.24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 2, 2020 |
| Jun 30, 2020 | -$1.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 |
| Mar 31, 2020 | -$0.79 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 |
| Dec 31, 2019 | -$0.79 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 |
| Jun 30, 2019 | -$0.97 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 |
| Mar 31, 2019 | -$0.84 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2019 |
| Dec 31, 2018 | -$0.84 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$3.35, after -$3.03 the year before. It was -$0.84 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$3.35 | N/A |
| Dec 31, 2024 | -$3.03 | N/A |
| Dec 31, 2023 | -$3.69 | -255.7% |
| Dec 31, 2022 | $2.37 | N/A |
| Dec 31, 2021 | -$1.60 | N/A |
| Dec 31, 2020 | -$4.91 | N/A |
| Dec 31, 2019 | -$2.60 | N/A |
| Dec 31, 2018 | -$0.84 | N/A |
Frequently Asked Questions About CGEM
When is Cullinan Oncology LLC's next earnings date?
Cullinan Oncology LLC's next earnings report is expected for Mar 8, 2027.
Did CGEM beat earnings estimates last quarter?
Yes. Cullinan Oncology LLC reported EPS of -$0.74 for the quarter ended Sep 30, 2026, above the -$0.79 estimate, a 6.33% surprise.
What EPS do analysts expect from CGEM next quarter?
The consensus EPS estimate for Cullinan Oncology LLC for the quarter ending Dec 31, 2026 is -$0.84 from 15 analysts, with estimates from -$1.14 to -$0.38.
How often does CGEM beat earnings estimates?
Cullinan Oncology LLC beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +1.21%.
CGEM pages: Overview, Earnings, Forecast, Financials, Competitors